Literature DB >> 20824268

[Perioperative antocoagulation in patients with prosthetic heart valves: recommendations].

D Wendt1, J A Piotrowski, B Schönfelder, G Marggraf, M Thielmann, H Jakob.   

Abstract

Lifelong anticoagulation, mainly with oral Vitamin K antagonists, represents the treatment of choice in patients with prosthetic heart valves to prevent thrombembolic complications. As a result, anticoagulant-related complications like excessive bleeding during interventions or surgical procedures will occur. Therefore, timely stopping of vitamin K antagonists prior to elective surgery is mandatory. However, based on the long half-life of all common vitamin K antagonists, interruption of oral anticoagulation will definitively lead to an increase of thrombembolic events. Hence, adequate bridging anticoagulation by temporary substitution of this therapy with heparin is necessary. This article gives a recommendation on the basis of the American College of Chest Physician and European Society of Cardiology current.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20824268     DOI: 10.1007/s00120-010-2361-1

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  8 in total

1.  Surgery in the geriatric patient: aging, the heart, emergencies, and us.

Authors:  Michael E Zenilman
Journal:  Arch Surg       Date:  2007-02

2.  Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology.

Authors:  Alec Vahanian; Helmut Baumgartner; Jeroen Bax; Eric Butchart; Robert Dion; Gerasimos Filippatos; Frank Flachskampf; Roger Hall; Bernard Iung; Jaroslaw Kasprzak; Patrick Nataf; Pilar Tornos; Lucia Torracca; Arnold Wenink
Journal:  Eur Heart J       Date:  2007-01-26       Impact factor: 29.983

3.  Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Jack Hirsh; Gordon Guyatt; Gregory W Albers; Robert Harrington; Holger J Schünemann
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

Review 4.  Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency.

Authors:  N P Clark
Journal:  Thromb Res       Date:  2008-09-21       Impact factor: 3.944

5.  Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer.

Authors:  Gilbert Habib; Bruno Hoen; Pilar Tornos; Franck Thuny; Bernard Prendergast; Isidre Vilacosta; Philippe Moreillon; Manuel de Jesus Antunes; Ulf Thilen; John Lekakis; Maria Lengyel; Ludwig Müller; Christoph K Naber; Petros Nihoyannopoulos; Anton Moritz; Jose Luis Zamorano
Journal:  Eur Heart J       Date:  2009-08-27       Impact factor: 29.983

6.  Developing quality indicators for elderly surgical patients.

Authors:  Marcia L McGory; Kenneth K Kao; Paul G Shekelle; Laurence Z Rubenstein; Michael J Leonardi; Janak A Parikh; Arlene Fink; Clifford Y Ko
Journal:  Ann Surg       Date:  2009-08       Impact factor: 12.969

7.  Comparison of safety of subcutaneous enoxaparin as outpatient anticoagulation bridging therapy in patients with a mechanical heart valve versus patients with nonvalvular atrial fibrillation.

Authors:  Hien Thuy Bui; Ashok Krisnaswami; Chieu-Uyen Le; James Chan; Bach-Nga Shenoy
Journal:  Am J Cardiol       Date:  2009-09-26       Impact factor: 2.778

Review 8.  Thrombolytic therapy of left-sided prosthetic valve thrombosis.

Authors:  P T Koller; K V Arom
Journal:  Chest       Date:  1995-12       Impact factor: 9.410

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.